QUOTE AND NEWS
New York Times  Apr 29  Comment 
Pressured by a proposal made directly to Medivation’s shareholders, the company said the $9.3 billion offer “substantially undervalues Medivation.”
newratings.com  Apr 29  Comment 
PARIS (dpa-AFX) - French drug maker Sanofi (SNYNF, SNY) reported Friday a higher profit in its first quarter, while net sales were hurt mainly by weak results in Diabetes unit and Venezuela. Excluding Venezuela. Aggregate Group sales increased 3...
The Hindu Business Line  Apr 29  Comment 
newratings.com  Apr 29  Comment 
Wall Street Journal  Apr 28  Comment 
Drugmakers are placing big bets on medicines they expect will command premium prices. Sanofi made an unsolicited, $9.3 billion offer to purchase Medivation. Separately, AbbVie agreed to pay $5.8 billion for Stemcentrx.
Financial Times  Apr 28  Comment 
Abbott, AbbVie and Sanofi announce separate purchases, taking 2016 transactions to $121bn
Clusterstock  Apr 28  Comment 
The French pharmaceuticals giant Sanofi has made a near-$10-billion (£6.85 billion) bid for the American biotech firm Medivation, which specialises in cancer treatments. In a letter sent to Medivation on Thursday, Sanofi's chief executive,...
New York Times  Apr 28  Comment 
Sanofi said that it made a private offer to acquire the prostate cancer drug maker nearly two weeks ago but did not receive a response.
The Economic Times  Apr 27  Comment 
The company has called an annual general meeting on Friday when it will seek approval from the shareholder to appoint these three directors.
newratings.com  Apr 26  Comment 
PARIS (dpa-AFX) - Medivation, Inc. (MDVN) confirmed it has received an unsolicited, non-binding proposal from Sanofi to acquire all outstanding shares of the company common stock for $52.50 in cash. Medivation said its stockholders are advised to...




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki